New Additions to First Light Management Team and Board of Directors
BEDFORD, Mass., November 2, 2017 (Newswire.com) - First Light Biosciences, a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAIs) announced today two new additions to the First Light team.
William Moffitt joins the First Light Biosciences’ board of directors as its chairman. Mr. Moffitt has held executive positions at Baxter Healthcare Corporation and American Hospital Supply. He has also led the point-of-care company I-Stat Corporation from its early research phase through commercialization and IPO to a premium acquisition by Abbott Labs in 2003. He subsequently took the clinical microbiology company Nanosphere through the development stage and IPO to sales.
Geoffrey A McKinley joins the First Light Biosciences team as Chief Product Development officer. Prior to First Light, Mr. McKinley held a management role at OpGen, Inc where he was responsible for the IVD instrument and assay development project. Some of his accomplishments included restructuring resources and re-engineering the quality system to meet FDA 21 CFR 820 (QSr) and ISO 13485 requirements. Prior strategic roles include AdvanDx4, GenturaDx, Osmetech plc, as well as various positions with bioMérieux, Inc. and Analytab Products, Inc. He is an author on 13 U.S. patents and received his Ph.D. in Microbiology from Colorado State University.
“We are at an exciting point in the evolution of our company,” said Don Straus, CEO and founder of First Light Biosciences. “The addition of experienced executives such as Bill and Geoff to key positions on our team will guide our development and delivery of our breakthrough technology.“
About First Light Biosciences
Based in Bedford, Massachusetts, First Light Biosciences is developing breakthrough automated medical diagnostic products for rapid, sensitive, and cost-effective detection of Healthcare Associated Infections (HAI). The products address the need for cost-effective and accurate diagnostics to meet the explosive growth in testing. New testing is being driven by clinical studies showing that testing for the infectious agents can help to dramatically lower the rate of hospital infections. Based on its proprietary MultiPath™ detection technology, First Light’s products combine the performance of the most advanced commercial laboratory tests with affordability and ease-of-use. To learn more, visit www.firstlightbio.com.
Contact:
Kelly Peterson
kelly@firstlightbio.com
Source: First Light Biosciences
